Blood DNA test may predict return of rare blood cancer
NCT ID NCT04893564
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is looking at whether pieces of tumor DNA found in the blood (called circulating tumor DNA) can help predict if Waldenström macroglobulinemia will come back after treatment. Researchers will collect blood and bone marrow samples from 90 patients after their first 6 months of therapy and follow them for up to 3 years. The goal is to see if the presence of this DNA is linked to a higher risk of relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients are at higher risk of their cancer returning, allowing for earlier intervention.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any change in patient care, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact